Plasmatic Coagulation Capacity Correlates With Inflammation and Abacavir Use During Chronic HIV Infection

Wouter A. van der Heijden, MD,a Jun Wan, MSc,b Lisa Van de Wijer, MD,a Martin Jaeger, PhD,a Mihai G. Netea, MD, PhD,a,c Andre J. van der Ven, MD, PhD,a Philip G. de Groot, PhD,b Mark Roest, PhD,b and Quirijn de Mast, MD, PhDa

Background: D-dimer concentrations in people living with HIV (PLHIV) on combination antiretroviral therapy (cART) are increased and have been linked to mortality. D-dimer is a biomarker of in vivo coagulation. In contrast to reports on D-dimer, data on coagulation capacity in PLHIV are conflicting. In this study, we assessed the effect of cART and inflammation on coagulation capacity.

Setting: We explored coagulation capacity using calibrated thrombin generation (TG) and linked this to persistent inflammation and cART in a cross-sectional study including PLHIV with viral suppression and uninfected controls.

Methods: We used multivariate analyses to identify independent factors influencing in vivo coagulation (D-dimer) and ex vivo coagulation capacity (TG).

Results: Among 208 PLHIV, 94 (45%) were on an abacavir-containing regimen. D-dimer levels (219.1 vs 170.5 ng/mL, \( P = 0.001 \)) and inflammatory makers (sCD14, sCD163, and high-sensitive C-reactive protein) were increased in PLHIV compared with those in controls (\( n = 56 \)). PLHIV experienced lower TG (reflected by endogenous thrombin potential [ETP]) when compared with controls, after correction for age, sex, and antiretroviral therapy. Abacavir use was independently associated with increased ETP. Prothrombin concentrations were strongly associated with ETP and lower in PLHIV on a non–abacavir-containing regimen compared with those in controls, suggesting consumption as a possible mechanism for HIV-associated reduction in TG. D-dimer concentrations were associated with inflammation, but not TG.

Conclusions: Abacavir use was associated with increased TG and could serve as an additional factor in the reported increase in thrombotic events during abacavir use. Increased exposure to triggers that propagate coagulation, such as inflammation, likely underlie increased D-dimer concentrations found in most PLHIV.

Key Words: D-dimer, thrombin generation, abacavir, inflammation, coagulation, thrombosis

J Acquir Immune Defic Syndr 2021;87:711–719

INTRODUCTION

Successful combination antiretroviral therapy (cART) has nearly normalized life expectancy of people living with HIV (PLHIV), although treatment is not able to fully reverse immune activation and persistent inflammation.1–3 This inflammation may increase the risk of thrombotic events.4 Although increased risk of venous thrombosis in PLHIV seems to be limited to those with incomplete CD4 recovery or with continuing viral replication,5,6 data on arterial thrombosis risk show an increased cardiovascular risk in well-treated PLHIV.7–9 There is an ongoing debate on the effect of cART, especially abacavir, on cardiovascular risk.10–15

D-dimers, which are soluble fibrin degradation products, are markers of coagulation activity in the body. HIV infection is associated with elevated D-dimer concentrations even in those with viral suppression.16–18 D-dimer concentrations are independently associated with overall mortality and the incidence of cardiovascular disease (CVD) and cancer in PLHIV.9,16,19 D-dimer concentrations are influenced by...
activation of the coagulation cascade itself and signals that provoke coagulation such as inflammation and endothelial activation. Indeed, the inflammatory markers sCD14, high-sensitive C-reactive protein (hsCRP), and sCD163 have been associated with D-dimer in PLHIV, suggesting a link between inflammation and in vivo coagulation activity in PLHIV.

The capacity of plasma to form thrombin is a critical determinant of in vivo plasmatic coagulation. Thrombin generation (TG) can be measured ex vivo to determine coagulation capacity in a standardized setting and has been used as a diagnostic tool for hypocoagulability and hypercoagulability states. In contrast to elevated D-dimer concentrations in PLHIV, available data on ex vivo TG in PLHIV are contradictory. This also applies to the possible roles of inflammation and cART on TG.

Hence, we measured TG and different coagulation markers in a cross-sectional cohort of cART treated, virally suppressed PLHIV and HIV-uninfected controls and related TG to markers of inflammation and cART. We hypothesized that TG is influenced by both persistent inflammation and cART.

**MATERIALS AND METHODS**

**Study Procedures**

This cross-sectional, prospective study was performed at the Radboud University Medical Center, a tertiary teaching hospital in the Netherlands. The study was conducted in accordance with the Declaration of Helsinki after approval of the ethics committee (CMO Arnhem-Nijmegen, the Netherlands; NL42561.091.12, 2012/550). This study was embedded in the Human Functional Genomics Project (HFGP; www.humanfunctionalgenomicsproject.org). Adult HIV-1-infected individuals and controls were concurrently enrolled after written informed consent was obtained. Inclusion criteria included suppressed viral load (<200 copies/mL) after cART use for at least 6 months. Exclusion criteria were the use of coumarin derivates or direct anticoagulant therapy, active hepatitis B or C infection, and/or signs of an infection other than HIV-1.

**Plasma TG Measured With and Without Thrombomodulin**

TG in platelet poor plasma (PPP) was measured with the “MIDICAT” technique, which is a modified calibrated TG [Calibrated Automated Thrombogram (CAT)] for the measurement of samples with low plasma volume. This technique maintains the plasma dilution ratio, whereas requiring only half of the volume (ie, 40 versus 80 μL per well) needed than the regular CAT technique. PPP was stored at −80°C until thawed at 37°C for 10 minutes before measurement. TG was triggered with 5 pM tissue factor (TF; Innovin; Siemens Healthcare Diagnostics, Marburg, Germany), 4 μM phospholipids (PL; Avanti Polar Lipids Inc., Alabaster, AL), and in the presence and absence of 7 nM thrombomodulin (TM; Synapse Research Institute, Maastricht, the Netherlands). The concentration of TM was chosen to inhibit the endogenous thrombin potential (ETP) by 50% in normal pooled plasma (NPP). TG parameters were calculated using specialized software from Thromboscope B.V. (Maastricht, the Netherlands). TG parameters (see Table, Supplemental Digital Content, http://links.lww.com/QAI/B606) including lag time (LT; minutes), time-to-peak (TTP; minutes), peak (nM), ETP (nM × minutes), and velocity index (VI; nM/min) were chosen for further analysis. The ETP, peak, and VI of tested subjects were normalized as the percentage of that of NPP tested without TM in the same run.

The sensitivity of the TG parameters to TM reflects the function of the anticoagulant protein C pathway. The TM sensitivity ratio of ETP (ETP-TMsr) was calculated as the ratio of ETP in the presence of TM and ETP in the absence of TM. The normalized TM sensitivity ratio of ETP (nETP-TMsr) was calculated by dividing the ETP-TMsr of subject by that of NPP in the same run. The nPeak-TMsr and nVI-TMsr were calculated similarly. An nTMsr value less than 1 means that the PPP of the tested subject has a better functioning protein C system than that of the NPP and vice versa.

**Plasma Markers of Coagulation and Inflammation**

Inflammatory markers sCD163 (Quantikine), sCD14 (Quantikine), and hsCRP (DuoSet) were determined in EDTA plasma by enzyme-linked immunosorbent assay (ELISA; all R&D system, Minneapolis, MI). D-dimer was measured by ELISA according to the manufacturer’s instructions (Abcam, Cambridge, United Kingdom).

The measurement of plasmatic fibrinogen was performed using the Clauss method on a STart4 analyzer (Diagnostica Stago, Asnières, France) with a known fibrinogen reagent (Dade Fibrinogen Determination Reagent, Siemens, Munich, Germany). Prothrombin (sheep antihuman prothrombin polyclonal antibody and horseradish peroxidase (HRP)-conjugated sheep antihuman prothrombin polyclonal antibody; Affinity Biologicals Inc., Ancaster, Canada), protein S (sheep antihuman protein S) IgG antibody and HRP-conjugated sheep antihuman protein S antibody from Affinity Biologicals, Inc., and von Willebrand factor (vWF; rabbit antihuman vWF and HRP-conjugated rabbit antihuman vWF; DAKO, Agilent, Santa Clara, CA) concentrations were performed with an in-house sandwich ELISA assay. In brief, 96-well microtiter plates (NUNC MaxiSorp; Thermo Fisher Scientific, Waltham, MA) were coated overnight at 4°C with capture antibody in a carbonate–bicarbonate coating buffer (pH 9.6) and blocked with 2% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 45 minutes at room temperature (RT) before adding diluted plasma samples and incubated at RT for 1.5 hours. The wells were then incubated with detection antibody in PBS/2%BSA for 2 hours at room temperature after washing. Plates were washed before addition of SIGMAFAST OPD (Sigma). After 30 minutes, the reaction was stopped with 3M sulfuric acid (H₂SO₄; Sigma). Optical densities (ODs) were measured at 490 nm using an ELx808 Absorbance Microplate Reader (Biotek, Bad Friedrichshall, Germany). A calibration curve of serial
diluted NPP was added to each plate. Consequently, the concentrations of prothrombin and protein S were expressed as the percentage of the normal NPP.

**Statistical Analysis**

R version 3.5.1 (CRAN-project) was used for analyses. Comparison between groups was performed by Mann–Whitney U test, Student t test, or $\chi^2$ test depending on data distribution. The primary outcome for TG used in our analyses was ETP. Other TG parameters were treated as exploratory parameters. The Benjamini–Hochberg procedure was performed on circulating markers and ETP comparisons (Fig. 2, Table 2) to correct for the false discovery rate (FDR). For univariate and multivariate linear regression, data of the dependent variable were transformed by log- or inverse rank transformation depending on distribution. All multivariate linear regression models include a parameter to correct for possible storage degradation or time of inclusion bias. The correlation matrix was performed using Spearman correlation coefficient. Missing data for all parameters were <2.5%, and comparisons were performed pairwise.

**RESULTS**

A total of 208 virally suppressed PLHIV on stable cART and 56 uninfected controls were concurrently measured and included in the analysis. Baseline characteristics can be found in Table 1. PLHIV were more often male subjects (91.3% vs 60.7%, $P = 0.001$) and older [52 (46–59) vs 30 (26–53) years, $P = 0.001$] when compared with HIV-uninfected controls. An abacavir-containing regimen was used by 94 PLHIV (45%), and 140 PLHIV (67%) used an integrase inhibitor (INSTI)-based regimen.

First, in vivo coagulation activity, determined by D-dimer, was increased in PLHIV compared with that in controls (219.1 vs 170.5 ng/mL, respectively, $P = 0.001$) (Table 2), as were all markers of inflammation (hsCRP, ...
TABLE 2. Markers of Inflammation

<table>
<thead>
<tr>
<th></th>
<th>PLHIV</th>
<th>HC</th>
<th>PLHIV vs HC</th>
<th>PLHIV—No ABC</th>
<th>PLHIV—ABC</th>
<th>Non-ABC vs ABC</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>208</td>
<td>56</td>
<td></td>
<td>114</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>D-dimer</td>
<td>219.1 (160.6, 334.8)</td>
<td>170.5 (122.0, 307.2)</td>
<td>0.002*</td>
<td>213.4 (158.6, 335.5)</td>
<td>221.9 (162.6, 334.2)</td>
<td>0.673</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>3.4 (2.8, 4.0)</td>
<td>3.2 (2.8, 4.1)</td>
<td>0.746</td>
<td>3.4 (2.8, 4.0)</td>
<td>3.3 (2.8, 4.0)</td>
<td>0.632</td>
</tr>
<tr>
<td>Prothrombin</td>
<td>109.0 (89.3, 135.1)</td>
<td>135.1 (102.4, 162.5)</td>
<td>&lt;0.001*</td>
<td>106.0 (87.1, 135.1)</td>
<td>113.4 (94.8, 134.8)</td>
<td>0.305</td>
</tr>
<tr>
<td>Protein S</td>
<td>91.4 (80.7, 110.3)</td>
<td>86.9 (72.7, 112.4)</td>
<td>0.121</td>
<td>91.7 (81.7, 109.4)</td>
<td>91.4 (78.2, 110.4)</td>
<td>0.937</td>
</tr>
<tr>
<td>vWf</td>
<td>42.7 (31.8, 59.4)</td>
<td>32.5 (24.4, 43.9)</td>
<td>&lt;0.001*</td>
<td>42.3 (31.6, 61.6)</td>
<td>43.0 (32.4, 57.3)</td>
<td>0.623</td>
</tr>
<tr>
<td>IFABP</td>
<td>499.6 (263.0, 717.1)</td>
<td>242.5 (112.9, 376.9)</td>
<td>&lt;0.001*</td>
<td>576.2 (287.4, 897.2)</td>
<td>400.6 (240.5, 619.2)</td>
<td>0.004*</td>
</tr>
<tr>
<td>hsCRP</td>
<td>1446 (608, 2735)</td>
<td>651 (205, 1179)</td>
<td>&lt;0.001*</td>
<td>1558 (624, 3285)</td>
<td>1192 (594, 2249)</td>
<td>0.337</td>
</tr>
<tr>
<td>sCD14</td>
<td>2139 (1778, 2625)</td>
<td>1789 (1502, 2071)</td>
<td>&lt;0.001*</td>
<td>2063 (1745, 2591)</td>
<td>2236 (1830, 2684)</td>
<td>0.193</td>
</tr>
<tr>
<td>sCD163</td>
<td>716.2 (525.6, 898.8)</td>
<td>517.3 (410.7, 578.1)</td>
<td>&lt;0.001*</td>
<td>765.8 (518.6, 916.1)</td>
<td>634.5 (487.8, 858.3)</td>
<td>0.019</td>
</tr>
<tr>
<td>ETP</td>
<td>86.6 (78.6, 99.6)</td>
<td>93.0 (83.3, 105.0)</td>
<td>0.011*</td>
<td>83.7 (74.7, 97.6)</td>
<td>90.2 (82.7, 101.6)</td>
<td>0.001*</td>
</tr>
<tr>
<td>LT</td>
<td>2.0 (1.7, 2.3)</td>
<td>2.0 (1.7, 2.0)</td>
<td>0.382</td>
<td>2.0 (1.7, 2.3)</td>
<td>2.0 (1.7, 2.3)</td>
<td>0.557</td>
</tr>
<tr>
<td>TTP</td>
<td>4.4 (4.0, 5.0)</td>
<td>4.3 (3.5, 5.0)</td>
<td>0.035</td>
<td>4.3 (4.0, 5.0)</td>
<td>4.4 (4.0, 5.0)</td>
<td>0.566</td>
</tr>
<tr>
<td>Peak</td>
<td>82.6 (70.0, 95.8)</td>
<td>88.1 (72.3, 101.5)</td>
<td>0.031</td>
<td>79.9 (65.2, 96.0)</td>
<td>85.8 (76.1, 95.7)</td>
<td>0.083</td>
</tr>
<tr>
<td>VI</td>
<td>78.1 (56.2, 102.7)</td>
<td>97.3 (64.0, 123.5)</td>
<td>0.001</td>
<td>76.4 (53.6, 102.5)</td>
<td>78.3 (61.2, 101.5)</td>
<td>0.566</td>
</tr>
<tr>
<td>Protein C activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LagT-TM</td>
<td>1.7 (1.4, 2.0)</td>
<td>1.7 (1.4, 2.0)</td>
<td>0.704</td>
<td>1.7 (1.4, 2.3)</td>
<td>1.7 (1.7, 2.0)</td>
<td>0.645</td>
</tr>
<tr>
<td>TTP-TM</td>
<td>3.7 (3.3, 4.0)</td>
<td>3.7 (3.3, 4.0)</td>
<td>0.641</td>
<td>3.7 (3.3, 4.0)</td>
<td>3.7 (3.3, 4.0)</td>
<td>0.982</td>
</tr>
<tr>
<td>ETP-TM</td>
<td>40.6 (27.9, 52.0)</td>
<td>50.1 (32.8, 76.2)</td>
<td>&lt;0.001*</td>
<td>41.0 (28.0, 51.1)</td>
<td>39.7 (26.3, 52.6)</td>
<td>0.706</td>
</tr>
<tr>
<td>VI-TM</td>
<td>49.6 (31.8, 62.4)</td>
<td>57.1 (39.8, 82.5)</td>
<td>0.002</td>
<td>50.9 (33.2, 61.6)</td>
<td>47.9 (29.9, 62.5)</td>
<td>0.553</td>
</tr>
<tr>
<td>nETP-TMSR</td>
<td>59.8 (38.6, 82.5)</td>
<td>71.9 (51.8, 112.5)</td>
<td>&lt;0.001*</td>
<td>62.1 (39.8, 85.4)</td>
<td>59.6 (33.2, 77.5)</td>
<td>0.509</td>
</tr>
<tr>
<td>nPeak-TMSR</td>
<td>0.9 (0.7, 1.2)</td>
<td>1.2 (0.8, 1.5)</td>
<td>0.001</td>
<td>0.9 (0.7, 1.2)</td>
<td>0.9 (0.6, 1.2)</td>
<td>0.183</td>
</tr>
<tr>
<td>nVI-TMSR</td>
<td>0.9 (0.8, 1.1)</td>
<td>1.1 (0.9, 1.3)</td>
<td>&lt;0.001*</td>
<td>1.0 (0.8, 1.1)</td>
<td>0.9 (0.8, 1.1)</td>
<td>0.185</td>
</tr>
</tbody>
</table>

*Significantly different between groups after FDR correction.

Marker of inflammation: hsCRP, soluble CD14, and soluble CD163. Marker of microbial translocation: plasma IFABP. Marker of endothelial activation: plasma vWF. Calibrated TG was triggered with 5 μM tissue factor, 4 μM phospholipids, and in the presence and absence of 7 nM TM. Lag time (LagT), TTP, ETP. Normalized Protein C activity (NSR). P values were calculated using the Mann–Whitney U test. Circulating factors and ETP as the primary outcome for TG were corrected for multiple testing using the Benjamini–Hochberg procedure (FDR). All remaining TG parameters were treated as exploratory parameters.

sCD14, and sCD163 and the microbial translocation marker IFABP (data summarized in Table 2). D-dimer was independently associated with age (B = 7.44, P < 0.001), and after correction for age and sex, the difference in D-dimer between PLHIV and uninfected controls disappeared (B = 0.154, P = 0.878; see Table 1, Supplemental Digital Content, http://links.lww.com/QAI/B606). The markers of inflammation and microbial translocation remained significantly increased in PLHIV compared with those of controls after correction for age and sex (see Table 1, Supplemental Digital Content, http://links.lww.com/QAI/B606). D-dimer concentrations correlated with markers of inflammation, IFABP, and endothelial activation (plasma vWF; Fig. 1).

Ex Vivo Coagulation Capacity by TG

Next, ex vivo coagulation capacity was determined by ex vivo calibrated TG in plasma. Overall, calibrated thrombin generation showed lower TG, most notably reduced ETP, our primary outcome regarding TG, in PLHIV compared with that in uninfected controls (Table 2, FDR-corrected). In addition, PLHIV experienced reduced peak thrombin formation and increased LT compared with HIV-negative controls (data summarized in Table 2). This difference in ETP persisted (FDR-corrected) only in a subgroup analysis of participants aged 40 years and older (see Table 2, Supplemental Digital Content, http://links.lww.com/QAI/B606), but disappeared in the subgroup of only men (see Table 3, Supplemental Digital Content, http://links.lww.com/QAI/B606). However, after correction for age and sex, none of the TG parameters were significantly different between both cohorts (see Table 1, Supplemental Digital Content, http://links.lww.com/QAI/B606). Most women used oral contraceptive during sampling, which may account for the strong changes in TG parameters when stratifying for sex in the uninfected cohort.29 Within the PLHIV cohort, no clear association was found between ETP and CD4 nadir, HIV duration, or current CD4 count (Fig. 1; see Table 5, Supplemental Digital Content, http://links.lww.com/QAI/B606). Higher current CD4 count and CD4 recovery were correlated with increased peak thrombin and ETP (data summarized in Table 5, Supplemental Digital Content, http://links.lww.com/QAI/B606), whereas HIV-RNA zenith and HIV duration were associated with decreased protein C activity (nETP-TMSr; see Table 4, Supplemental Digital Content, http://links.lww.com/QAI/B606). With the exception of nETP-TMSr, we found no associations between smoking and TG parameters (see Table 5, Supplemental Digital Content, http://links.lww.com/QAI/B606).
Inflammation and Ex Vivo Coagulation Capacity

Although inflammatory markers and D-dimer correlated positively, ETP did not correlate with any of the included inflammatory markers. Only LT and TTP correlated with sCD14, sCD163, and hsCRP (data shown in Fig. 1). Moreover, sCD163 showed a negative correlation with protein C activity (nETP-TMsr; $R^2 = 0.2$, $P = 0.05$, Fig. 1).

Increased TG in Abacavir- vs Non–abacavir-treated PLHIV

Next, we explored whether different antiretroviral drugs were associated with TG. There was no association between the use of a protease inhibitor, INSTI, or nonnucleoside reverse transcriptase inhibitor (NNRTI; Fig. 2) with ETP or any of the other TG parameters. By contrast, abacavir use was associated with an increased ETP [non-abacavir: 83.7% (74.7, 97.6) vs 90.2% (82.7, 101.6), $P = 0.001$; Fig. 3 and Table 2]. In addition, there was a trend toward higher peak thrombin concentrations in the abacavir group [79.9% (65.2, 96.0) vs 85.8% (76.1, 95.7) $P = 0.083$; Table 2]. This effect of abacavir on ETP was independent of age, sex, and inflammation (ETP: $B = 8.00$, $P = 0.006$; see Table 5, Supplemental Digital Content, http://links.lww.com/QAI/B606). Usage of tenofovir difumarate (TDF) was the most prescribed alternative for abacavir. As a consequence, TDF was associated with a reduced ETP in our cohort ($B = 27.86$, $P = 0.006$). However, in multivariate analysis, the effect of abacavir seemed to be larger than TDF on ETP. Therefore, we attributed the effect of NRTIs on ETP to abacavir in this study. To a similar extent, we could not clearly discriminate between lamivudine and abacavir in this cohort because this was the most prescribed combination of NRTIs (all data from multivariate analyses are tabulated in Table 4, Supplemental Digital Content, http://links.lww.com/QAI/B606). Because INSTI use was high in the abacavir group and showed a trend toward lower ETP, we corrected for INSTI use (B = -5.79, $P = 0.061$), and the effect of abacavir on ETP became more pronounced (ETP: B = 8.85, $P = 0.002$).

The abacavir-associated increase in ETP was not due to decreased protein C activity, a known inhibitor of plasmatic coagulation, because nETPsr was comparable between groups even after correcting for age, sex, and inflammation (abacavir: $B = -0.895$, $P = 0.37$).

In most analyses on abacavir-associated cardiovascular risk in treated PLHIV, there was a discrepancy between current use, past use (>6 months), and cumulative abacavir use (reviewed by Libbe et al.30). Current use of abacavir was more strongly associated with ETP in our cohort than cumulative use. When analysis was restricted to current abacavir users, cumulative exposure (in days) was not correlated with ETP ($B = 0.597$, $P = 0.552$).

When restricting the analysis to non-abacavir users, PLHIV had a decreased ETP, with increased lag time and more pronounced protein C activity (Table 2 and Table 6, Supplemental Digital Content, http://links.lww.com/QAI/B606), when compared with uninfected controls. In summary, our data show that abacavir use is associated with an increase in ex vivo coagulation capacity reflected by increased TG, whereas overall, PLHIV on a non-abacavir regimen showed a decreased coagulation capacity measured by TG.

Mechanisms of Decreased TG

Decreased TG and increased D-dimer concentrations suggest consumption of coagulation factors. Indeed,
Prothrombin concentrations were decreased in PLHIV (Fig. 3C), even after correcting for age and sex [PLHIV: 109.0% (89.3, 135.1), HC: 135.1% (102.4, 162.5), \( P = 0.001 \); see Table 1, Supplemental Digital Content, http://links.lww.com/QAI/B606]. Although prothrombin concentrations were decreased in PLHIV compared with those in controls, fibrinogen concentrations [PLHIV: 3.4 mg/mL (2.8, 4.0), HC: 3.2 mg/mL (2.8, 4.1), \( P = 0.746 \)] did not differ between groups (Figs. 3A, C). Furthermore, prothrombin was strongly correlated with ETP parameters in both PLHIV and uninfected controls (Fig. 3D and Table 6, Supplemental Digital Content, http://links.lww.com/QAI/B606), suggesting that the reduced concentration of prothrombin may underlie the observed decrease in TG in PLHIV. Reduced production of prothrombin and other coagulation factors (by the liver) was deemed unlikely because of similar concentrations of protein S [PLHIV: 91.7% (81.7, 109.4), HC: 86.9% (72.7, 112.4), \( P = 0.163 \), Fig. 3E] and fibrinogen. No difference in

**FIGURE 2.** Endogenous thrombin potential stratified per cART use. ETP (nM × min) were normalized as the percentage of that of NPP tested in the same run. ABC, Abacavir; INSTI, integrase inhibitor; RAL, raltegravir, DTG, dolutegravir. Values were compared using the Mann–Whitney \( U \) test. Data are depicted according to the Tukey procedure. Comparisons are corrected for multiple testing using the Benjamini–Hochberg procedure. ETP remained significantly higher in ABC users compared with non-ABC after FDR correction.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
prothrombin or fibrinogen could be observed when PLHIV were stratified based on abacavir use (Table 2).

DISCUSSION

In a cohort of virally suppressed PLHIV on chronic cART, we show that abacavir use was associated with increased TG compared with that of non-abacavir regimens. Overall, PLHIV exhibited reduced TG compared with HIV-uninfected controls, which was associated with lower plasma concentrations of prothrombin. PLHIV had higher concentrations of inflammatory markers, which correlated with D-dimer concentrations, but not with TG parameters.

TG is a diagnostic tool for hypercoagulability states. This is not limited to venous thrombosis and may also include arterial thrombosis. The use of abacavir has been linked to an...
increased risk of acute cardiovascular events in different studies.\textsuperscript{10–13} By contrast, abacavir use does not seem to be associated with an increased incidence of venous thrombosis.\textsuperscript{5} Increased platelet activation was suggested to underlie the excess cardiovascular risk in users of abacavir.\textsuperscript{32–34} Although increased platelet activation was not observed in all studies.\textsuperscript{35} A recent study found that abacavir led to an inflammatory and prothrombotic endothelial phenotype promoting in vivo platelet activation through endothelial microparticles.\textsuperscript{36} The increased TG in abacavir use could also be caused by endothelial dysfunction and possible prothrombotic endothelial microparticles.\textsuperscript{36,37} In addition, thrombin directly activates platelets, so our finding of increased TG capacity in abacavir users may as such contribute to increased platelet activation and CVD.\textsuperscript{38} In contrast to our results, a study by Jung et al.\textsuperscript{24} showed no difference in TG for abacavir use, but only with a limited sample size of 27 individuals in the abacavir group.

Although inflammation was increased in PLHIV, we found no increase in TG. Moreover, the subgroup analysis of non-abacavir users showed a slight decrease in TG in PLHIV compared with that in uninfected controls. This observation is in line with earlier observations, showing decreased TG in long-term–treated PLHIV.\textsuperscript{25} In this study, we confirm these results using a cohort of long-term–treated PLHIV on more recently recommended cART regimens. Regarding possible mechanisms, consumption of clotting factors could play a role because prothrombin concentrations were decreased with a concurrent increase in D-dimer in the total PLHIV group. Fibrinogen concentrations were similar across all groups, but fibrinogen is a well-known acute phase protein and could, therefore, reflect inflammation rather than coagulation capacity.\textsuperscript{39} Furthermore, decreased production of (pro)coagulation factors was deemed less likely because other factors produced by the liver such as fibrinogen and protein S were similar across groups.

More recent articles have used in silico TG as a proxy for plasmatic coagulation potential and showed that this calculated TG correlates with development of CVD.\textsuperscript{40} Furthermore, in the hallmark randomized controlled SMART trial investigating CD4-guided treatment interruption, in silico TG was lower in PLHIV without ART and ongoing viral replication compared with that in cART–treated PLHIV.\textsuperscript{41,42} Although D-dimer mirrors coagulation and fibrinolysis in vivo, in vitro TG reflects actual hemostatic potential of the plasmatic coagulation pathways.\textsuperscript{22} We confirmed that D-dimers indeed correlated with endothelial activation (eg, vWF) and inflammation (eg, sCD163), but found no such relation with TG parameters in PLHIV. This suggests that increased D-dimer concentrations are primarily influenced by increased provoking signals for coagulation, such as endothelial activation and inflammation during HIV infection. However, increased plasmatic coagulation capacity could still play a role in CVD in PLHIV, as was shown by a case–control study using in silico TG.\textsuperscript{42} A significant role for plasmatic coagulation and increased TG has been shown in clinical studies including uninfected patients at risk for CVD.\textsuperscript{31} Because PLHIV are known for increased inflammation and endothelial activation, an abacavir–associated potentiation of the plasmatic coagulation capacity could, therefore, still result in increased risk for arterial thrombosis.

Interestingly, protein S activity was higher in PLHIV and correlated with inflammation (sCD163), thereby reducing the overall plasmatic coagulation capacity. This rebalancing of the anticoagulant and procoagulant pathway during HIV infection mimics the rebalancing of hemostasis seen in liver disease.\textsuperscript{43} Monocyte and macrophage activation (sCD14 and sCD163) correlated with LT and TTP. These parameters are mostly influenced by an increase in tissue factor pathway inhibitor (TFPI).\textsuperscript{44} This TFPI is known to be increased in PLHIV.\textsuperscript{45} Although endothelial cells and platelets mainly produce TFPI, monocytes are known producers of TFPI too and could increase production on activation.\textsuperscript{44}

LIMITATIONS AND STRENGTHS

The cross-sectional design of our study does not allow to draw causal inferences. Furthermore, the independent increase in TG seen in abacavir treatment could be affected through indication bias whereby treatment selection is influenced by patient characteristics. Yet, in our case, abacavir was preferably given to people with a decreased cardiovascular risk profile, which was reflected in our cohort with a trend toward lower CVD risk factors in the abacavir–treated group. Second, because TDF was the most prescribed alternative to abacavir, we cannot fully rule out that TDF inhibit TG. Yet, it will not change the conclusions that abacavir is associated with increased TG compared with non-abacavir users. To a similar extent, we cannot exclude the possibility that lamivudine is involved in this difference because lamivudine was prescribed concurrently to abacavir in most patients. Third, we could not correlate TG parameters with clinical outcomes, as was performed in the study reporting on in silico TG. Although in silico TG can be calculated from plasma markers measured in (long-term) stored EDTA plasma, our functional assay of calibrated TG (CAT) requires citrated plasma, which is not regularly collected in large-scale cohorts. Actual measurement of thrombin formation using the CAT method is more precise than the modeling of the in silico TG method because CAT also includes possible unknown confounders such as cART use or other unknown factors. Therefore, CAT better reflects actual hemostatic potential in complex disease states such as an HIV infection. Furthermore, owing to lower number of women in our study, generalizability of our findings to women is limited and warrants further study. Our cohort only consists of virally suppressed PLHIV on long-term treatment and reflects the current HIV-infected population. Thus, our data cannot be used to draw conclusions about patients who are still severely immune compromised or with ongoing viral replication.

In conclusion, abacavir use was associated with increased TG, and this increase could serve as an additional factor in the reported increase in thrombotic events during abacavir use. Increased exposure to triggers that propagate coagulation, such as inflammation, and endothelial activation likely underlie increased D-dimer concentrations found in most PLHIV.

REFERENCES


